Jafron Biomedical Co Ltd
SZSE:300529
Net Margin
Jafron Biomedical Co Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
J
|
Jafron Biomedical Co Ltd
SZSE:300529
|
17.6B CNY |
31%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
224.5B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
184.2B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
151B USD |
12%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
140.2B USD |
13%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
107.8B USD |
13%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
52.9B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.8B USD |
8%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.7B USD |
75%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
260.4B CNY |
33%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
35.5B USD |
23%
|
Jafron Biomedical Co Ltd
Glance View
In the heart of China's bustling Guangdong province, Jafron Biomedical Co., Ltd. has carved a distinguished niche in the world of biomedicine since its inception. This innovative company, recognized as a leader in the hemoperfusion field, has built its reputation on a foundation of pioneering blood purification technologies. By developing and manufacturing an array of hemoperfusion devices, Jafron offers critical solutions that aid in the removal of toxins from the bloodstream, thus improving outcomes for patients suffering from various systemic toxic reactions and kidney-related disorders. Their state-of-the-art hemoperfusion cartridges, meticulously designed for efficiency, are instrumental in managing and treating conditions such as chronic kidney disease and liver dysfunction. This relentless pursuit of quality is bolstered by a dedicated research division that harmonizes clinical insights with scientific innovation, ensuring Jafron stays at the forefront of clinical demand. Jafron Biomedical thrives on a robust business model that fuses direct sales with an expansive network of partnerships. This dual approach not only amplifies their market reach but also enables the company to establish solid footholds in key domestic and international markets. By collaborating with healthcare institutions and medical device distributors, Jafron ensures its products deliver critical health solutions to a broad clientele. The revenue streams are mainly anchored in the sales of its hemoperfusion products and through strategic expansions in emerging markets. As global health standards evolve and the demand for advanced medical solutions expands, Jafron is positioned to sustain its growth momentum by continually innovating in response to the global demand for efficient blood purification therapies. Through these methods, Jafron not only augments its economic footprint but also underscores its commitment to enhancing global healthcare standards.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Jafron Biomedical Co Ltd's most recent financial statements, the company has Net Margin of 30.6%.
You don't have any saved screeners yet